Alzheimer's breakthrough signals game changer for biotech sector

clock • 4 min read
Linden Thomson and Peter Hughes if AXA IM

Linden Thomson and Peter Hughes if AXA IM

The accelerated approval of the first new Alzheimer's treatment in almost two decades looks set to drive a new wave of biotech innovation and investment.

Alzheimer's disease is a type of dementia that affects memory and other cognitive abilities. Globally, around 50 million people suffer from dementia; there are almost 10 million new cases annually - and...

To continue reading this article...

Join Investment week

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now


Already an Investment Week